-
Product Insights
NewD4 Dopamine Receptor – Drugs In Development, 2024
The D4 Dopamine Receptor pipeline drugs market research report outlays comprehensive information on the D4 Dopamine Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Respiratory, Immunology, and Cardiovascular which include indications of Parkinson's Disease, Major Depressive Disorder, Idiopathic Pulmonary Fibrosis, Psoriasis, and Pulmonary Arterial Hypertension. It also reviews key players involved in D4...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Carbidopa + Levodopa) in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Carbidopa + Levodopa) in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Carbidopa + Levodopa) in Parkinson's Disease Drug Details: The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ND-0612 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ND-0612 in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ND-0612 in Parkinson's Disease Drug Details: ND-0612 is under development as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Foscarbidopa + Foslevodopa) in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Foscarbidopa + Foslevodopa) in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Foscarbidopa + Foslevodopa) in Parkinson's Disease Drug Details: Foscarbidopa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pipamperone Dihydrochloride in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pipamperone Dihydrochloride in Major Depressive Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pipamperone Dihydrochloride in Major Depressive Disorder Drug Details: Pipamperone dihydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pramipexole in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pramipexole in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pramipexole in Parkinson's Disease Drug Details: Pramipexole is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levodopa in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levodopa in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levodopa in Parkinson's Disease Drug Details: Levodopa is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brilaroxazine in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brilaroxazine in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brilaroxazine in Parkinson's Disease Drug Details: RP-5063 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brilaroxazine in Psychosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Brilaroxazine in Psychosis Drug Details: RP-5063 is under development for the treatment of schizophrenia, schizoaffective...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brilaroxazine in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brilaroxazine in Pulmonary Arterial Hypertension report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s...